Schwarz Builds its Business in the Public Eye
Schwarz Pharma is a publicly-held mid-sized pharmaceutical company in Germany with a business model that emphasizes its marketing and sales strengths in Germany. It does little R&D of its own, preferring to license in products from outside. To compete against others seeking to license in products, it offers its strengths in the German market. Its recent deal with Novartis AG to co-market the hypertension drug valsartan is an example of this strategy.
You may also be interested in...
The European Medicines Agency commits to exploring real-world data as part of its new Regulatory Science Strategy to 2025.
Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.
A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.